SEC Form 4 · accession 0001171843-17-003991
Anika Therapeutics, Inc. · ANIK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles H Sherwood
Officer — President, CEO, Director · Director
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000898437
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 3, 2017 | S | 5,965 | $50.00 | D | 246,740 | D | |
| Common StockF2 | Jul 5, 2017 | S | 8,236 | $50.06 | D | 238,504 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On July 3, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,965 shares in multiple trades ranging from $50.00 to $50.02. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected.
- F2On July 5, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 8,236 shares in multiple trades ranging from $50.00 to $50.25. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected.